[{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"56dc1b56-646f-4648-9e26-4b51bc644b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04317105","created_at":"2021-01-18T20:55:21.759Z","updated_at":"2025-02-25T16:37:48.003Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","source_id_and_acronym":"NCT04317105","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PD-L1 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"c392c236-bf01-4f33-b758-84c02e4596c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939897","created_at":"2021-01-18T19:24:01.905Z","updated_at":"2025-02-25T16:52:29.645Z","phase":"Phase 1","brief_title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03939897","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2020","start_date":" 06/17/2020","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-02-04"},{"id":"13809b89-05e8-41ef-8215-b7d1aaa392e9","acronym":"NCI-2018-01880","url":"https://clinicaltrials.gov/study/NCT03884998","created_at":"2021-01-18T19:08:46.177Z","updated_at":"2025-02-25T17:36:15.593Z","phase":"Phase 1","brief_title":"Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03884998 - NCI-2018-01880","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/26/2019","start_date":" 02/26/2019","primary_txt":" Primary completion: 07/16/2025","primary_completion_date":" 07/16/2025","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-01-29"},{"id":"83a4cc91-840b-45a5-8084-819f697c1e10","acronym":"CA209-8LC","url":"https://clinicaltrials.gov/study/NCT03711058","created_at":"2021-01-18T18:11:36.282Z","updated_at":"2025-02-25T14:27:43.047Z","phase":"Phase 1/2","brief_title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","source_id_and_acronym":"NCT03711058 - CA209-8LC","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 06/14/2022","primary_completion_date":" 06/14/2022","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-13"},{"id":"51bc21f1-64c8-4e95-bcfa-4fdd977e48c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572763","created_at":"2021-01-18T21:50:00.501Z","updated_at":"2025-02-25T17:24:50.909Z","phase":"Phase 1/2","brief_title":"Copanlisib Plus Venetoclax in R/R DLBCL","source_id_and_acronym":"NCT04572763","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-20"},{"id":"739a6ead-49a8-4524-b971-bdd0dec1f85b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05082025","created_at":"2021-10-18T12:53:16.001Z","updated_at":"2025-02-25T17:25:18.256Z","phase":"Phase 2","brief_title":"Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations","source_id_and_acronym":"NCT05082025","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN deletion","tags":["ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 10/29/2026","primary_completion_date":" 10/29/2026","study_txt":" Completion: 10/29/2026","study_completion_date":" 10/29/2026","last_update_posted":"2024-12-18"},{"id":"98bf47af-2f07-41d0-8aba-0ad0045bf73a","acronym":"CHRONOS-1","url":"https://clinicaltrials.gov/study/NCT01660451","created_at":"2021-01-18T07:10:10.841Z","updated_at":"2025-02-25T17:20:13.895Z","phase":"Phase 2","brief_title":"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT01660451 - CHRONOS-1","lead_sponsor":"Bayer","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 227","initiation":"Initiation: 11/19/2012","start_date":" 11/19/2012","primary_txt":" Primary completion: 06/22/2016","primary_completion_date":" 06/22/2016","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2024-07-17"},{"id":"1d394ddd-86a9-4b8f-a2a2-adf734a97239","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502733","created_at":"2023-12-06T17:15:36.704Z","updated_at":"2024-07-02T16:34:25.709Z","phase":"Phase 1","brief_title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","source_id_and_acronym":"NCT03502733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"413409a2-0792-4de1-a64e-d4d1801140e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586661","created_at":"2021-01-18T17:38:28.376Z","updated_at":"2024-07-02T16:34:27.534Z","phase":"Phase 1","brief_title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03586661","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-11"},{"id":"d2401e9e-4fcb-4143-a93d-a94dce3674a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939272","created_at":"2021-06-25T22:54:05.033Z","updated_at":"2024-07-02T16:34:58.910Z","phase":"Phase 1/2","brief_title":"Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04939272","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • PAX5 overexpression","tags":["BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • PAX5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 11/23/2024","study_completion_date":" 11/23/2024","last_update_posted":"2024-06-04"},{"id":"4aeeae3b-239d-409e-b580-694a2f0d8715","acronym":"NCI-2022-06209","url":"https://clinicaltrials.gov/study/NCT05490771","created_at":"2022-08-08T12:59:00.924Z","updated_at":"2024-07-02T16:35:01.772Z","phase":"Phase 2","brief_title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","source_id_and_acronym":"NCT05490771 - NCI-2022-06209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 01/06/2021","primary_completion_date":" 01/06/2021","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-23"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"784f7253-5a1d-4544-9fbf-f9c89407e818","acronym":"BrUOG 360","url":"https://clinicaltrials.gov/study/NCT04253262","created_at":"2021-01-18T20:40:05.687Z","updated_at":"2025-02-25T17:24:31.844Z","phase":"Phase 1/2","brief_title":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT04253262 - BrUOG 360","lead_sponsor":"Brown University","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" BRIP1 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRIP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-05"},{"id":"af734147-b4c2-4351-87af-14a4c5e4f2fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04462471","created_at":"2021-01-18T21:27:12.136Z","updated_at":"2024-07-02T16:35:17.410Z","phase":"Phase 1","brief_title":"Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers","source_id_and_acronym":"NCT04462471","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/26/2020","start_date":" 06/26/2020","primary_txt":" Primary completion: 09/29/2023","primary_completion_date":" 09/29/2023","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2024-02-28"},{"id":"5bf72cfc-6950-4d08-8b26-9b400483706a","acronym":"COPA-R-CHOP","url":"https://clinicaltrials.gov/study/NCT04263584","created_at":"2021-01-18T20:43:20.108Z","updated_at":"2025-02-25T17:24:34.757Z","phase":"Phase 2","brief_title":"Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL","source_id_and_acronym":"NCT04263584 - COPA-R-CHOP","lead_sponsor":"University Hospital Muenster","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 06/19/2020","start_date":" 06/19/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-01-04"},{"id":"b95e17bd-b01c-41cd-a864-4f421a03ffc8","acronym":"FIL_Copa-RB","url":"https://clinicaltrials.gov/study/NCT04433182","created_at":"2022-05-05T21:54:09.918Z","updated_at":"2024-07-02T16:35:25.830Z","phase":"Phase 2","brief_title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04433182 - FIL_Copa-RB","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Aliqopa (copanlisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 08/18/2020","start_date":" 08/18/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-12-19"},{"id":"eeba7518-b503-49ac-924b-812045b1db22","acronym":"","url":"https://clinicaltrials.gov/study/NCT04933617","created_at":"2021-06-22T16:52:46.443Z","updated_at":"2024-07-02T16:35:26.366Z","phase":"Phase 1","brief_title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","source_id_and_acronym":"NCT04933617","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Aliqopa (copanlisib) • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-12-13"},{"id":"3407a620-7d06-4881-aec9-ac80feff6767","acronym":"Panther","url":"https://clinicaltrials.gov/study/NCT02705859","created_at":"2021-01-18T13:13:39.850Z","updated_at":"2024-07-02T16:35:30.273Z","phase":"Phase 1","brief_title":"Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)","source_id_and_acronym":"NCT02705859 - Panther","lead_sponsor":"Cancer Trials Ireland","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2023-11-06"},{"id":"c6b840a9-cde6-463f-aaed-d7a3262f6ba6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03735628","created_at":"2021-01-18T18:17:51.915Z","updated_at":"2025-02-25T17:10:37.499Z","phase":"Phase 1b/2","brief_title":"An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03735628","lead_sponsor":"Bayer","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/17/2018","start_date":" 10/17/2018","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2023-10-06"},{"id":"49297bcc-58c4-446b-9d67-218005819ada","acronym":"NRG-GY029","url":"https://clinicaltrials.gov/study/NCT05295589","created_at":"2022-03-26T01:54:07.007Z","updated_at":"2024-07-02T16:35:35.787Z","phase":"Phase 2","brief_title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","source_id_and_acronym":"NCT05295589 - NRG-GY029","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • MUC16","pipe":" | ","alterations":" BRCA2 mutation • HRD","tags":["BRCA1 • BRCA2 • HRD • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Aliqopa (copanlisib) • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 03/17/2023","primary_completion_date":" 03/17/2023","study_txt":" Completion: 03/17/2023","study_completion_date":" 03/17/2023","last_update_posted":"2023-09-26"},{"id":"6f327e64-d115-4ce3-9cf0-d18bfa2173a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03803761","created_at":"2021-01-18T18:48:06.877Z","updated_at":"2024-07-02T16:35:35.810Z","phase":"Phase 1/2","brief_title":"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer","source_id_and_acronym":"NCT03803761","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/13/2019","start_date":" 02/13/2019","primary_txt":" Primary completion: 02/19/2022","primary_completion_date":" 02/19/2022","study_txt":" Completion: 02/19/2022","study_completion_date":" 02/19/2022","last_update_posted":"2023-09-25"},{"id":"689316f3-0db1-4949-8172-a7e734d12cae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03474744","created_at":"2021-01-18T17:07:45.971Z","updated_at":"2025-02-25T17:23:50.581Z","phase":"Phase 2","brief_title":"Copanlisib and Rituximab in Marginal Zone Lymphoma Patients","source_id_and_acronym":"NCT03474744","lead_sponsor":"Christian Buske","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Aliqopa (copanlisib) • Truxima (rituximab-abbs)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/15/2019","start_date":" 12/15/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2023-08-25"}]